Literature DB >> 31387880

Clonal expansion of CAR T cells harboring lentivector integration in the CBL gene following anti-CD22 CAR T-cell therapy.

Nirali N Shah1, Haiying Qin1, Bonnie Yates1, Ling Su2, Haneen Shalabi1, Mark Raffeld3, Mark A Ahlman4, Maryalice Stetler-Stevenson5, Constance Yuan5, Shuang Guo2, Siyuan Liu2, Stephen H Hughes6, Terry J Fry1,7,8, Xiaolin Wu2.   

Abstract

Entities:  

Year:  2019        PMID： 31387880      PMCID： PMC6693002          DOI： 10.1182/bloodadvances.2019000219

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  31 in total

1.  HIV-1 integration in the human genome favors active genes and local hotspots.

Authors:  Astrid R W Schröder; Paul Shinn; Huaming Chen; Charles Berry; Joseph R Ecker; Frederic Bushman
Journal:  Cell       Date:  2002-08-23       Impact factor: 41.582

2.  Abrogating Cbl-b in effector CD8(+) T cells improves the efficacy of adoptive therapy of leukemia in mice.

Authors:  Ingunn M Stromnes; Joseph N Blattman; Xiaoxia Tan; Sara Jeevanjee; Hua Gu; Philip D Greenberg
Journal:  J Clin Invest       Date:  2010-09-20       Impact factor: 14.808

Review 3.  Activation of T cells: releasing the brakes by proteolytic elimination of Cbl-b.

Authors:  M Lienhard Schmitz
Journal:  Sci Signal       Date:  2009-06-23       Impact factor: 8.192

4.  Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia.

Authors:  Marina Cavazzana-Calvo; Emmanuel Payen; Olivier Negre; Gary Wang; Kathleen Hehir; Floriane Fusil; Julian Down; Maria Denaro; Troy Brady; Karen Westerman; Resy Cavallesco; Beatrix Gillet-Legrand; Laure Caccavelli; Riccardo Sgarra; Leila Maouche-Chrétien; Françoise Bernaudin; Robert Girot; Ronald Dorazio; Geert-Jan Mulder; Axel Polack; Arthur Bank; Jean Soulier; Jérôme Larghero; Nabil Kabbara; Bruno Dalle; Bernard Gourmel; Gérard Socie; Stany Chrétien; Nathalie Cartier; Patrick Aubourg; Alain Fischer; Kenneth Cornetta; Frédéric Galacteros; Yves Beuzard; Eliane Gluckman; Frederick Bushman; Salima Hacein-Bey-Abina; Philippe Leboulch
Journal:  Nature       Date:  2010-09-16       Impact factor: 49.962

5.  LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1.

Authors:  S Hacein-Bey-Abina; C Von Kalle; M Schmidt; M P McCormack; N Wulffraat; P Leboulch; A Lim; C S Osborne; R Pawliuk; E Morillon; R Sorensen; A Forster; P Fraser; J I Cohen; G de Saint Basile; I Alexander; U Wintergerst; T Frebourg; A Aurias; D Stoppa-Lyonnet; S Romana; I Radford-Weiss; F Gross; F Valensi; E Delabesse; E Macintyre; F Sigaux; J Soulier; L E Leiva; M Wissler; C Prinz; T H Rabbitts; F Le Deist; A Fischer; M Cavazzana-Calvo
Journal:  Science       Date:  2003-10-17       Impact factor: 47.728

6.  An adenoviral vector encoding dominant negative Cbl lowers the threshold for T cell activation in post-thymic T cells.

Authors:  Yuanyuan Zha; Thomas F Gajewski
Journal:  Cell Immunol       Date:  2007-09-25       Impact factor: 4.868

7.  Ablation of Cbl-b provides protection against transplanted and spontaneous tumors.

Authors:  Jeffrey Y Chiang; Ihn Kyung Jang; Richard Hodes; Hua Gu
Journal:  J Clin Invest       Date:  2007-03-15       Impact factor: 14.808

8.  Transcription start regions in the human genome are favored targets for MLV integration.

Authors:  Xiaolin Wu; Yuan Li; Bruce Crise; Shawn M Burgess
Journal:  Science       Date:  2003-06-13       Impact factor: 47.728

9.  Adoptive transfer of siRNA Cblb-silenced CD8+ T lymphocytes augments tumor vaccine efficacy in a B16 melanoma model.

Authors:  Reinhard Hinterleitner; Thomas Gruber; Christa Pfeifhofer-Obermair; Christina Lutz-Nicoladoni; Alexander Tzankov; Manfred Schuster; Josef M Penninger; Hans Loibner; Günther Lametschwandtner; Dominik Wolf; Gottfried Baier
Journal:  PLoS One       Date:  2012-09-04       Impact factor: 3.240

10.  Spontaneous tumor rejection by cbl-b-deficient CD8+ T cells.

Authors:  Stefanie Loeser; Karin Loser; Martijn S Bijker; Manu Rangachari; Sjoerd H van der Burg; Teiji Wada; Stefan Beissert; Cornelis J M Melief; Josef M Penninger
Journal:  J Exp Med       Date:  2007-04-02       Impact factor: 14.307
View more
  24 in total

1.  The future of cellular immunotherapy for childhood leukemia.

Authors:  Challice L Bonifant; Sarah K Tasian
Journal:  Curr Opin Pediatr       Date:  2020-02       Impact factor: 2.856

2.  T Cell Receptor Engineered Lymphocytes for Cancer Therapy.

Authors:  Meagan R Rollins; Ellen J Spartz; Ingunn M Stromnes
Journal:  Curr Protoc Immunol       Date:  2020-06

Review 3.  Gene editing to enhance the efficacy of cancer cell therapies.

Authors:  Tara Murty; Crystal L Mackall
Journal:  Mol Ther       Date:  2021-10-18       Impact factor: 11.454

4.  CAR T-cell Therapy Meets Clonal Hematopoiesis.

Authors:  Ugur Uslu; Carl H June
Journal:  Blood Cancer Discov       Date:  2022-09-06

5.  CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial.

Authors:  Nirali N Shah; Steven L Highfill; Haneen Shalabi; Bonnie Yates; Jianjian Jin; Pamela L Wolters; Amanda Ombrello; Seth M Steinberg; Staci Martin; Cindy Delbrook; Leah Hoffman; Lauren Little; Anusha Ponduri; Haiying Qin; Haris Qureshi; Alina Dulau-Florea; Dalia Salem; Hao-Wei Wang; Constance Yuan; Maryalice Stetler-Stevenson; Sandhya Panch; Minh Tran; Crystal L Mackall; David F Stroncek; Terry J Fry
Journal:  J Clin Oncol       Date:  2020-04-14       Impact factor: 44.544

6.  Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice.

Authors:  Dan Li; Nan Li; Yi-Fan Zhang; Haiying Fu; Mingqian Feng; Dina Schneider; Ling Su; Xiaolin Wu; Jing Zhou; Sean Mackay; Josh Kramer; Zhijian Duan; Hongjia Yang; Aarti Kolluri; Alissa M Hummer; Madeline B Torres; Hu Zhu; Matthew D Hall; Xiaoling Luo; Jinqiu Chen; Qun Wang; Daniel Abate-Daga; Boro Dropublic; Stephen M Hewitt; Rimas J Orentas; Tim F Greten; Mitchell Ho
Journal:  Gastroenterology       Date:  2020-02-12       Impact factor: 22.682

Review 7.  Childhood Cancer: Occurrence, Treatment and Risk of Second Primary Malignancies.

Authors:  Sebastian Zahnreich; Heinz Schmidberger
Journal:  Cancers (Basel)       Date:  2021-05-26       Impact factor: 6.639

8.  Sleeping Beauty-engineered CAR T cells achieve antileukemic activity without severe toxicities.

Authors:  Chiara F Magnani; Giuseppe Gaipa; Federico Lussana; Daniela Belotti; Giuseppe Gritti; Sara Napolitano; Giada Matera; Benedetta Cabiati; Chiara Buracchi; Gianmaria Borleri; Grazia Fazio; Silvia Zaninelli; Sarah Tettamanti; Stefania Cesana; Valentina Colombo; Michele Quaroni; Giovanni Cazzaniga; Attilio Rovelli; Ettore Biagi; Stefania Galimberti; Andrea Calabria; Fabrizio Benedicenti; Eugenio Montini; Silvia Ferrari; Martino Introna; Adriana Balduzzi; Maria Grazia Valsecchi; Giuseppe Dastoli; Alessandro Rambaldi; Andrea Biondi
Journal:  J Clin Invest       Date:  2020-11-02       Impact factor: 14.808

Review 9.  Beyond the storm - subacute toxicities and late effects in children receiving CAR T cells.

Authors:  Haneen Shalabi; Juliane Gust; Agne Taraseviciute; Pamela L Wolters; Allison B Leahy; Carlos Sandi; Theodore W Laetsch; Lori Wiener; Rebecca A Gardner; Veronique Nussenblatt; Joshua A Hill; Kevin J Curran; Timothy S Olson; Colleen Annesley; Hao-Wei Wang; Javed Khan; Marcelo C Pasquini; Christine N Duncan; Stephan A Grupp; Michael A Pulsipher; Nirali N Shah
Journal:  Nat Rev Clin Oncol       Date:  2021-01-25       Impact factor: 66.675

10.  CAR T cells targeting tumor-associated exons of glypican 2 regress neuroblastoma in mice.

Authors:  Nan Li; Madeline B Torres; Madeline R Spetz; Ruixue Wang; Luyi Peng; Meijie Tian; Christopher M Dower; Rosa Nguyen; Ming Sun; Chin-Hsien Tai; Natalia de Val; Raul Cachau; Xiaolin Wu; Stephen M Hewitt; Rosandra N Kaplan; Javed Khan; Brad St Croix; Carol J Thiele; Mitchell Ho
Journal:  Cell Rep Med       Date:  2021-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.